Astrazeneca Share News (AZN)

UPDATE 2-GSK warns on profits as weak lung drug sales hit

* 2014 EPS growth cut to "broadly flat" from 4-8 percent * Q2 sales 5.56 bln pounds vs consensus 5.76 bln * Q2 core EPS 19.1 pence vs consensus 21.3p * Shares fall more than 6 percent (Adds analyst reaction, CEO comments) By Ben Hirschler LONDON, July 23 (Reuters)

UPDATE 1-Top U.S. lawmaker wants corporate tax loophole 'plugged now'

(Adds Hatch comments, paragraphs 4-9) By Kevin Drawbaugh WASHINGTON, July 22 (Reuters) - Immediate government action is needed to stop U.S. corporations from avoiding federal taxes by shifting their tax domiciles overseas through deals known as inversions, the head of the U.S. Senate

CORRECT: AstraZeneca's MedImmune Teams With Advaxis For Cancer Trial

Top U.S. lawmaker wants corporate tax loophole 'plugged now'

By Kevin Drawbaugh WASHINGTON, July 22 (Reuters) - Immediate government action is needed to plug a loophole that allows U.S. corporations to avoid federal taxes by shifting their tax domiciles overseas through deals known as inversions, the head of the U.S. Senate Finance Committee said on

UK MIDDAY BRIEFING: Royal Mail's Parcels Business Fails To Deliver

RPT-U.S. Senate panel to debate wave of corporate tax-avoidance deals

(Repeats story published late on Monday and earlier on Tuesday) By Kevin Drawbaugh WASHINGTON, July 21 (Reuters) - As more U.S. corporations do deals to cut taxes by shifting their tax domiciles overseas, the Senate Finance Committee will hold a hearing on Tuesday focused on these tra

TOP NEWS: Bullish ARM Holdings Lifts Interim Dividend As Profits Rise

AstraZeneca's MedImmune Teams With Advaxis For Combined Cancer Trial

UK MORNING BRIEFING: Anglo American Leads Opening Gains

AstraZeneca widens cancer immunotherapy net with Advaxis trial

LONDON, July 22 (Reuters) - AstraZeneca is casting its net wider in the hot cancer immunotherapy field through a clinical trial collaboration with U.S. biotech firm Advaxis that will test drugs from both companies in combination. Britain-based AstraZeneca - the target of an unsuccessful $1

RPT-U.S. Senate panel to debate wave of corporate tax-avoidance deals

(Repeats story published late on Monday) By Kevin Drawbaugh WASHINGTON, July 21 (Reuters) - As more U.S. corporations do deals to cut taxes by shifting their tax domiciles overseas, the Senate Finance Committee will hold a hearing on Tuesday focused on these transactions known as inve

U.S. Senate panel to debate wave of corporate tax-avoidance deals

By Kevin Drawbaugh WASHINGTON, July 21 (Reuters) - As more U.S. corporations do deals to cut taxes by shifting their tax domiciles overseas, the Senate Finance Committee will hold a hearing on Tuesday focused on these transactions known as inversions. Nine such deals have been agreed

Drugmakers to share neglected compounds with British academia

LONDON, July 22 (Reuters) - A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening ties between industry and external scientists. British business minister Vince Cable anno

Broker tips: GlaxoSmithKline, AstraZeneca, Housebuilders

Panmure Gordon said it is "not expecting fireworks" from GlaxoSmithKline's (GSK) second-quarter results due out next Wednesday. "In light of our recent downgrade to forecasts due to exchange rate headwinds, we are expecting another tough quarter. China has not washed through completely either and g

Exane BNP Paribas expects Pfizer to return with better offer for Astra

Exane BNP Paribas sees at least a 50% chance that US pharmaceutical giant Pfizer will return with a sweetened offer for UK rival AstraZeneca (AZN) following its failed takeover earlier this year. The bank said it expects another approach in November, when restrictions under takeover panel rules exp